Search

Your search keyword '"Romagnoli, V."' showing total 247 results
Start Over Author "Romagnoli, V."
247 results on '"Romagnoli, V."'

1. T.12.2: THE LEVELS OF AFP, PIVKA-II AND GPC-3 SERUM BIOMARKERS AT DIAGNOSIS CORRELATE WITH HCC CLINICAL-PATHOLOGICAL FEATURES AND WITH OVERALL SURVIVAL

Author

Damone, F., primary, Caviglia, G.P., additional, Colombatto, P., additional, Ricco, G., additional, Oliveri, F., additional, Gaia, S., additional, Romagnoli, V., additional, Cavallone, D., additional, Rolle, E., additional, Coco, B., additional, Salvati, A., additional, Surace, L., additional, Carucci, P., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2024
Full Text
View/download PDF

5. Cancer cells and tumor vasculature dynamics analyzed by bio-mathematical modeling in HCC patients with different response to TKIs, TACE and TARE

Author

Damone, F., primary, Colombatto, P., additional, Ricco, G., additional, Oliveri, F., additional, Civitano, L., additional, Romagnoli, V., additional, Cavallone, D., additional, Demirtas, C.O., additional, Boraschi, P., additional, Scalise, P., additional, Crocetti, L., additional, Bargellini, I., additional, Coco, B., additional, Salvati, A., additional, Surace, L., additional, Boni, G., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2022
Full Text
View/download PDF

6. Pattern of macrovascular invasion in hepatocellular carcinoma

Author

Guarino, M., Cucchetti, A., Pontillo, G., Farinati, F., Benevento, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Rodolfo, S., Cabibbo, G., Marra, F., Mega, A., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Giannini, E. G., Morisco, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Rampoldi, D., Santi, V., Forgione, A., Granito, A., Muratori, L., Piscaglia, F., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Pelizzaro, F., Imondi, A., Sartori, A., Penzo, B., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., Pieri, G., de Matthaeis, N., Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Olivari, A., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, F., Berardinelli, D., Ercolani, G., Napoli, L., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Capasso, M., Fiorentino, A., Pignata, L., Cossiga, V., Romagnoli, V., Guarino M., Cucchetti A., Pontillo G., Farinati F., Benevento F., Rapaccini G.L., Di Marco M., Caturelli E., Zoli M., Rodolfo S., Cabibbo G., Marra F., Mega A., Gasbarrini A., Svegliati-Baroni G., Foschi F.G., Missale G., Masotto A., Nardone G., Raimondo G., Azzaroli F., Vidili G., Oliveri F., Trevisani F., Giannini E.G., Morisco F., Biselli M., Caraceni P., Garuti F., Gramenzi A., Neri A., Rampoldi D., Santi V., Forgione A., Granito A., Muratori L., Piscaglia F., Sansone V., Tovoli F., Dajti E., Marasco G., Ravaioli F., Cappelli A., Golfieri R., Mosconi C., Renzulli M., Cela E.M., Facciorusso A., Pelizzaro F., Imondi A., Sartori A., Penzo B., Cacciato V., Casagrande E., Moscatelli A., Pellegatta G., Pieri G., de Matthaeis N., Allegrini G., Lauria V., Ghittoni G., Pelecca G., Chegai F., Coratella F., Ortenzi M., Olivari A., Inno A., Marchetti F., Busacca A., Camma C., Di Martino V., Rizzo G.E.M., Franze M.S., Saitta C., Sauchella A., Bevilacqua V., Borghi A., Gardini A.C., Conti F., Berardinelli D., Ercolani G., Napoli L., Campani C., Di Bonaventura C., Gitto S., Coccoli P., Malerba A., Capasso M., Fiorentino A., Pignata L., Cossiga V., Romagnoli V., Guarino, M., Cucchetti, A., Pontillo, G., Farinati, F., Benevento, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Rodolfo, S., Cabibbo, G., Marra, F., Mega, A., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Giannini, E. G., Morisco, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Rampoldi, D., Santi, V., Forgione, A., Granito, A., Muratori, L., Piscaglia, F., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Pelizzaro, F., Imondi, A., Sartori, A., Penzo, B., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., Pieri, G., de Matthaeis, N., Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Olivari, A., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, F., Berardinelli, D., Ercolani, G., Napoli, L., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Capasso, M., Fiorentino, A., Pignata, L., Cossiga, V., and Romagnoli, V.

Subjects
Ablation Techniques, Male, Registrie, Cirrhosis, Clinical Biochemistry, Mesenteric Vein, loco-regional treatment, 030204 cardiovascular system & hematology, Biochemistry, Gastroenterology, surgery, Antineoplastic Agent, Liver disease, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, cirrhosis, hepatocellular carcinoma, portal vein thrombosis, transplantation, Ascites, Ablation Technique, Registries, 030212 general & internal medicine, Chronic, Settore MED/12 - Gastroenterologia, Portal Vein, Liver Diseases, Liver Neoplasms, General Medicine, Middle Aged, Sorafenib, Prognosis, Hepatitis B, Alcoholic, Hepatitis C, Tumor Burden, Survival Rate, Italy, Liver Neoplasm, Hepatocellular carcinoma, Ascite, Female, medicine.symptom, Liver cancer, Human, medicine.medical_specialty, Carcinoma, Hepatocellular, Prognosi, Antineoplastic Agents, End Stage Liver Disease, 03 medical and health sciences, Mesenteric Veins, Hepatitis B, Chronic, Internal medicine, medicine, Humans, Hepatectomy, Neoplasm Invasiveness, portal vein thrombosi, Liver Diseases, Alcoholic, Aged, Neoplasm Invasivene, Performance status, business.industry, Carcinoma, Settore MED/09 - MEDICINA INTERNA, Patient Acuity, Hepatocellular, Hepatitis C, Chronic, medicine.disease, Liver Transplantation, Transplantation, Liver function, business, cirrhosi
Abstract

Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed to evaluate interactions between MaVI, clinical variables and treatment, exploring the inter-relationship determining overall survival. Results: MaVI prevalence was 11.1%, and median survival of these patients was 6.0months (95% CI, 5.1-7.1). MaVI was associated with younger age at diagnosis, presence of symptoms, worse Performance Status (PS) and liver function, high alphafetoprotein levels and large HCCs. MaVI extension was associated with worse PS, ascites and greater impairment in liver function. RPA identified patients' categories with different treatment indications and survival, ranging from 2.4months in those with PS>1 and ascites, regardless of MaVI extension (receiving best supportive care in 90.3% of cases), to 14.1months in patients with PS 0-1, no ascites and Vp1-Vp2 MaVI (treated with surgery in 19.1% of cases). Conclusions: MaVI presence and extension, together with PS and ascites, significantly affect patients' survival and treatment selection. The decision tree based on these parameters may help assess patients' prognosis and inform therapeutic decisions.

Published
2021

7. Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients

Author

Colombatto, P., primary, Damone, F., additional, Ricco, G, additional, Oliveri, F., additional, Civitano, L., additional, Romagnoli, V., additional, Cavallone, D., additional, Demirtas, C.O., additional, Boraschi, P., additional, Scalise, P., additional, Crocetti, L., additional, Bargellini, I., additional, Coco, B., additional, Salvati, A., additional, Surace, L., additional, Urbani, L., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2022
Full Text
View/download PDF

9. OC.04.9 A SINGLE CENTER, LARGE LONG TERM COHORT STUDY OF THE RELATIONS BETWEEN MUTATIONS IN BASIC-CORE-PROMOTER AND PRE-C REGIONS OF HEPATITIS B VIRUS DNA AND CLINICPATHOLOGIC OUTCOME OF HBEAG-NEGATIVE/ANTI-HBEPOSITIVE PHASE

Author

Cavallone, D., primary, Ricco, G., additional, Flichman, D., additional, Moriconi, F., additional, Colombatto, P., additional, Bleve, P., additional, Coco, B., additional, Oliveri, F., additional, Romagnoli, V., additional, Salvati, A., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

11. AF.84 BIOIMAGING, BIOCHEMICAL AND GENETIC MARKERS TO STRATIFY PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN CLINICAL PRACTICE: A SINGLE CENTER COHORT STUDY

Author

Salvati, A., primary, De Rosa, L., additional, Faita, F., additional, Cavallone, D., additional, Ricco, G., additional, Colombatto, P., additional, Coco, B., additional, Romagnoli, V., additional, Oliveri, F., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

12. AF.96 MODELING HEPATOCELLULAR CARCINOMA CELLS DYNAMICS BY SEROLOGICAL AND IMAGING BIOMARKERS TO EXPLAIN COMPLETE RESPONSE TO SORAFENIB

Author

Colombatto, P., primary, Demirtas, C.O., additional, Ricco, G., additional, Civitano, L., additional, Boraschi, P., additional, Scalise, P., additional, Cavallone, D., additional, Oliveri, F., additional, Romagnoli, V., additional, Bleve, P., additional, Coco, B., additional, Salvati, A., additional, Urbani, L., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

13. Pattern of macrovascular invasion in hepatocellular carcinoma

Author

Guarino, Mariateresa, Cucchetti, A., Pontillo, G., Farinati, F., Benevento, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Rodolfo, S., Cabibbo, G., Marra, F., Mega, A., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Giannini, E. G., Morisco, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Rampoldi, D., Santi, V., Forgione, Alessandra, Granito, A., Muratori, L., Piscaglia, F., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Pelizzaro, F., Imondi, A., Sartori, A., Penzo, B., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., Pieri, G., De Matthaeis, Nicoletta, Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Olivari, Elena Armida, Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, Francesco, Berardinelli, D., Ercolani, G., Napoli, L., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Capasso, Monica, Fiorentino, Alice, Pignata, L., Cossiga, V., Romagnoli, V., Guarino M., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Forgione A., de Matthaeis N., Olivari A., Conti F., Capasso M., Fiorentino A., Guarino, Mariateresa, Cucchetti, A., Pontillo, G., Farinati, F., Benevento, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Rodolfo, S., Cabibbo, G., Marra, F., Mega, A., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Giannini, E. G., Morisco, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Rampoldi, D., Santi, V., Forgione, Alessandra, Granito, A., Muratori, L., Piscaglia, F., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Pelizzaro, F., Imondi, A., Sartori, A., Penzo, B., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., Pieri, G., De Matthaeis, Nicoletta, Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Olivari, Elena Armida, Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, Francesco, Berardinelli, D., Ercolani, G., Napoli, L., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Capasso, Monica, Fiorentino, Alice, Pignata, L., Cossiga, V., Romagnoli, V., Guarino M., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Forgione A., de Matthaeis N., Olivari A., Conti F., Capasso M., and Fiorentino A.

Abstract

Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed to evaluate interactions between MaVI, clinical variables and treatment, exploring the inter-relationship determining overall survival. Results: MaVI prevalence was 11.1%, and median survival of these patients was 6.0 months (95% CI, 5.1-7.1). MaVI was associated with younger age at diagnosis, presence of symptoms, worse Performance Status (PS) and liver function, high alphafetoprotein levels and large HCCs. MaVI extension was associated with worse PS, ascites and greater impairment in liver function. RPA identified patients' categories with different treatment indications and survival, ranging from 2.4 months in those with PS > 1 and ascites, regardless of MaVI extension (receiving best supportive care in 90.3% of cases), to 14.1 months in patients with PS 0-1, no ascites and Vp1-Vp2 MaVI (treated with surgery in 19.1% of cases). Conclusions: MaVI presence and extension, together with PS and ascites, significantly affect patients' survival and treatment selection. The decision tree based on these parameters may help assess patients' prognosis and inform therapeutic decisions.

Published
2021

14. The changing scenario of hepatocellular carcinoma in Italy: an update

Author

Garuti, F., Neri, A., Avanzato, F., Gramenzi, A., Rampoldi, D., Rucci, P., Farinati, F., Giannini, E. G., Piscaglia, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Brunetto, M. R., Trevisani, F., Biselli, M., Caraceni, P., Santi, V., Granito, A., Muratori, L., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., De Matthaeis, Nicoletta, Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Biasini, E., Olivani, A., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Berardinelli, D., Borghi, A., Gardini, A. C., Conti, Francesco, Cucchetti, A., Dall'Aglio, A. C., Ercolani, G., Campani, C., Di Bonaventura, C., Gitto, S., Malerba, P. C. A., Capasso, Monica, Guarino, Mariateresa, Oliveri, F., Romagnoli, V., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), de Matthaeis N., Conti F., Capasso M., Guarino M., Garuti, F., Neri, A., Avanzato, F., Gramenzi, A., Rampoldi, D., Rucci, P., Farinati, F., Giannini, E. G., Piscaglia, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Brunetto, M. R., Trevisani, F., Biselli, M., Caraceni, P., Santi, V., Granito, A., Muratori, L., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., De Matthaeis, Nicoletta, Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Biasini, E., Olivani, A., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Berardinelli, D., Borghi, A., Gardini, A. C., Conti, Francesco, Cucchetti, A., Dall'Aglio, A. C., Ercolani, G., Campani, C., Di Bonaventura, C., Gitto, S., Malerba, P. C. A., Capasso, Monica, Guarino, Mariateresa, Oliveri, F., Romagnoli, V., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), de Matthaeis N., Conti F., Capasso M., and Guarino M.

Abstract

Background and aims: Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of aetiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years. Methods: Retrospective analysis of the Italian Liver Cancer (ITA.LI.CA) database included 6034 HCC patients managed in 23 centres from 2004 to 2018. Patients were divided into three groups according to the date of cancer diagnosis (2004-2008, 2009-2013 and 2014-2018). Results: The main results were: (i) a progressive patient ageing; (ii) a progressive increase of non-viral cases and, particularly, of ‘metabolic’ and ‘metabolic + alcohol’ HCCs; (iii) a slightly decline of cases diagnosed under surveillance, but with an incremental use of the semiannual schedule; (iv) a favourable cancer stage migration; (v) an increased use of radiofrequency ablation to the detriment of percutaneous ethanol injection; (vi) improved outcomes of ablative and transarterial treatments; (vii) an improved overall survival (adjusted for the lead time in surveyed patients) in the last calendar period, particularly in viral patients; (viii) a large gap between the number of potential candidates (according to oncologic criteria and age) to liver transplant and that of transplanted patients. Conclusions: During the last 15 years several aspects of HCC scenario have changed, as well as its management. The improvement in patient survival observed in the last period was likely because of a larger use of thermal ablation with respect to the less effective alcohol injection and to an improved management of intermediate stage patients.

Published
2021

16. Modeling hepatocellular carcinoma cells dynamics by serolo-gical and imaging biomarkers in patients with response to sorafenib and/or regorafenib

Author

Colombatto, P., primary, Demirtas, C.O., additional, Ricco, G., additional, Civitano, L., additional, Boraschi, P., additional, Scalise, P., additional, Cavallone, D., additional, Oliveri, F., additional, Romagnoli, V., additional, Bleve, P., additional, Coco, B., additional, Salvati, A., additional, Urbani, L., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

18. A single center, large long-term cohort study of the relations between mutations in Basic-Core-Promoter and pre-C regions of Hepatitis B virus DNA and clinic-pathologic outcome of HBeAg-negative/anti-HBe-positive phase

Author

Cavallone, D., primary, Ricco, G., additional, Flichman, D., additional, Moriconi, F., additional, Colombatto, P., additional, Bleve, P., additional, Coco, B., additional, Oliveri, F., additional, Romagnoli, V., additional, Salvati, A., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

23. OC.05.3: MODELING CANCER CELLS AND TUMOR VASCULATURE DYNAMICS BY SERUM BIOMARKERS IN HCC PATIENTS WITH DIFFERENT RESPONSE TO TKIS, TACE AND TARE SUGGESTS A SYNERGISTIC EFFECT OF SYSTEMIC AND ENDOVASCULAR TREATMENTS.

Author

Damone, F., Colombatto, P., Ricco, G., Oliveri, F., Civitano, L., Romagnoli, V., Cavallone, D., Demirtas, C.O., Boraschi, P., Scalise, P., Crocetti, L., Bozzi, E., Coco, B., Salvati, A., Surace, L., Bonino, F., and Brunetto, M.R.

Published
2024
Full Text
View/download PDF

26. OC.01.6 THE CT1 MULTI-PARAMETRIC MRI VALUE IS MORE SENSITIVE AND RELIABLE THAN TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE MONITORING OF INTRA-HEPATIC INFLAMMATION/FIBROSIS RESPONSE TO DAA THERAPY IN CHC PATIENTS

Author

Salvati, A., primary, Martini, N., additional, Mckay, A., additional, Coco, B., additional, Colombatto, P., additional, Ricco, G., additional, Fiippo, O., additional, Romagnoli, V., additional, Faita, F., additional, Bonino, F., additional, Chiappino, D., additional, and Brunetto, M., additional

Published
2019
Full Text
View/download PDF

28. HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial

Author

Almasio, P., Colombatto, P., Brunetto, M., Maina, A., Romagnoli, V., Rumi, M., Ascione, A., Pinzello, G., Mondelli, M., Muratori, L., Rappuoli, R., Rosa, D., Houghton, M., Abrignani, S., Bonino, F., Almasio, PL, Colombatto, P, Brunetto, MR, Maina, AM, Romagnoli, V, Almasio, P, Rumi, MG, Ascione, A, Pinzello, G, Mondelli, M, Muratori, L, Rappuoli, R, Rosa, D, Houghton, M, Abrignani, S, and Bonino, F

Subjects
HCV vaccine
Abstract

Hepatitis C virus (HCV) vaccines may be able to increase viral clearance in combination with antiviral therapy. We analysed viral dynamics and HCV-specific immune response during retreatment for experienced patients in a phase Ib study with E1E2MF59 vaccine. Seventy-eight genotype 1a/1b patients [relapsers (30), partial responders (16) and nonresponders (32) to interferon-(IFN)/ribavirin-(RBV)] were randomly assigned to vaccine (V:23), Peg-IFNα2a-180-ug/qw and ribavirin 1000-1200-mg/qd for 48 weeks (P/R:25), or their combination (P/R + V:30). Vaccine (100 μg/0.5 mL) was administered intramuscularly at week 0-4-8-12-24-28-32-36. Neutralizing of binding (NOB) antibodies and lymphocyte proliferation assay (LPA) for E1E2-specific-CD4 + T cells were performed at week 0-12-16-48. Viral kinetics were analysed up to week 16. The vaccine was safe, and a sustained virological response (SVR) was achieved in 4 P/R + V and 2 P/R patients. Higher SVR rates were observed in prior relapsers (P/R + V = 27.3%; P/R = 12.5%). Higher NOB titres and LPA indexes were found at week 12 and 16 in P/R + V as compared to P/R patients (P = 0.023 and 0.025, P = 0.019 and

Published
2014

29. In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy

Author

Ricco, G., primary, Cavallone, D., additional, Pontisso, P., additional, Fassina, G., additional, Gallotta, A., additional, Colombatto, P., additional, Oliveri, F., additional, Romagnoli, V., additional, Coco, B., additional, Salvati, A., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2017
Full Text
View/download PDF

30. Low viremic HBeAg negative HBsAg carriers: Clinical outcome and non invasive diagnostic accuracy for chronic hepatitis B or inactive infection by combinations of HBV markers

Author

Oliveri, F., primary, Surace, L., additional, Cavallone, D., additional, Colombatto, P., additional, Ricco, G., additional, Salvati, N., additional, Coco, B., additional, Romagnoli, V., additional, Gattai, R., additional, Salvati, A., additional, Moriconi, F., additional, Yuan, Q., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2017
Full Text
View/download PDF

31. In hepatitis C infected patients with cirrhosis squamous cell carcinoma antigen (SCCA)-IgM levels may contribute to identify the individual risk of hepatocellular carcinoma development after antiviral therapy

Author

Ricco, G., primary, Cavallone, D., additional, Pontisso, P., additional, Fassina, G., additional, Gallotta, A., additional, Colombatto, P., additional, Oliveri, F., additional, Romagnoli, V., additional, Coco, B., additional, Salvati, A., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2017
Full Text
View/download PDF

32. Middle lobe syndrome in children today

Author

Romagnoli, V. Priftis, K.N. De Benedictis, F.M.

Abstract

Middle lobe syndrome in children is a distinct clinical and radiographic entity that has been well described in the pediatric literature. However, issues regarding its etiology, clinical presentation, and management continue to puzzle the clinical practitioner. Pathophysiologically, there are two forms of middle lobe syndrome, namely obstructive and nonobstructive. Middle lobe syndrome may present as symptomatic or asymptomatic, as persistent or recurrent atelectasis, or as pneumonitis or bronchiectasis of the middle lobe and/or lingula. A lower threshold of performing a chest radiograph is warranted in children with persistent or recurrent nonspecific respiratory symptoms, particularly if there is clinical deterioration, in order to detect middle lobe syndrome and to initiate a further diagnostic and therapeutic workup. © 2014 Elsevier Ltd.

Published
2014

33. Phenotype and disease course of early-onset pediatric inflammatory bowel disease

Author

Aloi, M, Lionetti, P, Barabino, A, Guariso, Graziella, Costa, S, Fontana, M, Romano, C, Lombardi, G, Miele, E, Alvisi, P, Diaferia, P, Baldi, M, Romagnoli, V, Gasparetto, M, DI PAOLA, M, Muraca, M, Pellegrino, S, Cucchiara, S, Martelossi, S, on behalf of SIGENP IBD Group, Marina, Aloi, Paolo, Lionetti, Arrigo, Barabino, Graziella, Guariso, Stefano, Costa, Massimo, Fontana, Claudio, Romano, Giuliano, Lombardi, Miele, Erasmo, Patrizia, Alvisi, Paolo, Diaferia, Maurizio, Baldi, Vittorio, Romagnoli, Marco, Gasparetto, Monica Di, Paola, Monica, Muraca, Salvatore, Pellegrino, Salvatore, Cucchiara, and Stefano, Martelossi

Subjects
Male, medicine.medical_specialty, Adolescent, early onset, Ulcerative, Disease, Inflammatory bowel disease, Severity of Illness Index, Crohn Disease, children, inflammatory bowel disease, Internal medicine, Severity of illness, medicine, Humans, Immunology and Allergy, Colitis, Family history, Age of Onset, Child, Preschool, Children, Early onset, Child, Preschool, Colitis, Ulcerative, Disease Progression, Female, Follow-Up Studies, Infant, Infant, Newborn, Phenotype, Gastroenterology, business.industry, medicine.disease, Newborn, Ulcerative colitis, digestive system diseases, Age of onset, business
Abstract

BACKGROUND: Early-onset (EO) pediatric inflammatory bowel diseases (IBD) seem to be more extensive than those with a later onset. To test this hypothesis, we examined the phenotype and disease course of patients with IBD diagnosis at 0 to 5 years, compared with the ranges 6 to 11 and 12 to 18 years. METHODS: Anatomic locations and behaviors were assessed according to Paris classification in 506 consecutive patients: 224 Crohn's disease, 245 ulcerative colitis, and 37 IBD-unclassified. RESULTS: Eleven percent of patients were in the range 0 to 5 years, 39% in 6 to 11 years, and 50% in 12 to 18 years. Ulcerative colitis was the most frequent diagnosis in EO-IBD and in 6- to 11-year-old group, whereas Crohn's disease was predominant in older children. A classification as IBD-unclassified was more common in the range 0 to 5 years compared with the other groups (P < 0.005). EO Crohn's disease showed a more frequent isolated colonic (P < 0.005) and upper gastrointestinal involvement than later-onset disease. Sixty-two percent of the patients in the 0 to 5 years range had pancolonic ulcerative colitis, compared with 38% of 6 to 11 years (P = 0.02) and 31% of 12-18 years (P = 0.002) range. No statistical difference for family history for IBD was found in the 3-year age groups. Therapies at the diagnosis were similar for all children. However, at latest follow-up, a significantly higher proportion of younger children were under steroids compared with older groups (P < 0.05). Surgical risk did not differ according to age. CONCLUSIONS: EO-IBD exhibits an extensive phenotype and benefit from aggressive treatment strategies, although surgical risk is similar to later-onset disease. A family history for IBD is not common in EO disease.

Published
2014

34. HCV E1E2-MF59vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial

Author

Colombatto, P, Brunetto, M R, Maina, A M, Romagnoli, V, Almasio, P, Rumi, M G, Ascione, A, Pinzello, G, Mondelli, M, Muratori, L, Rappuoli, R, Rosa, D, Houghton, M, Abrignani, S, Bonino, F, P. Colombatto, M. R. Brunetto, A. M. Maina, V. Romagnoli, P. Almasio, M. G. Rumi, A. Ascione, G. Pinzello, M. Mondelli, L. Muratori, R. Rappuoli, D. Rosa, M. Houghton, S. Abrignani, and F. Bonino

Subjects
CD4-Positive T-Lymphocytes, Squalene, Viral Hepatitis Vaccines, Drug-Related Side Effects and Adverse Reactions, viral kinetics, Polysorbates, VACCINE, Antiviral Agents, Injections, Intramuscular, immune response, Polyethylene Glycols, viral kinetic, Adjuvants, Immunologic, Ribavirin, Humans, neutralizing antibodies, HCV, interferon, vaccine, Cell Proliferation, Vaccines, Synthetic, Interferon-alpha, Original Articles, Hepatitis C Antibodies, Hepatitis C, Chronic, Viral Load, Antibodies, Neutralizing, Combined Modality Therapy, Recombinant Proteins, Treatment Outcome, RNA, Viral
Abstract

Hepatitis C virus (HCV) vaccines may be able to increase viral clearance in combination with antiviral therapy. We analysed viral dynamics and HCV-specific immune response during retreatment for experienced patients in a phase Ib study with E1E2MF59 vaccine. Seventy-eight genotype 1a/1b patients [relapsers (30), partial responders (16) and nonresponders (32) to interferon-(IFN)/ribavirin-(RBV)] were randomly assigned to vaccine (V:23), Peg-IFNα2a-180-ug/qw and ribavirin 1000–1200-mg/qd for 48 weeks (P/R:25), or their combination (P/R + V:30). Vaccine (100 μg/0.5 mL) was administered intramuscularly at week 0-4-8-12-24-28-32-36. Neutralizing of binding (NOB) antibodies and lymphocyte proliferation assay (LPA) for E1E2-specific-CD4 + T cells were performed at week 0-12-16-48. Viral kinetics were analysed up to week 16. The vaccine was safe, and a sustained virological response (SVR) was achieved in 4 P/R + V and 2 P/R patients. Higher SVR rates were observed in prior relapsers (P/R + V = 27.3%; P/R = 12.5%). Higher NOB titres and LPA indexes were found at week 12 and 16 in P/R + V as compared to P/R patients (P = 0.023 and 0.025, P = 0.019 and

Published
2014

45. P1202 EARLY PREDICTION OF SUSTAINED VIROLOGIC RESPONSE BY HCV CORE ANTIGEN KINETICS IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON PLUS RIBAVIRIN

Author

Ricco, G., primary, Moriconi, F., additional, Colombatto, P., additional, Oliveri, F., additional, Cavallone, D., additional, Ciccorossi, P., additional, Coco, B., additional, Romagnoli, V., additional, Rastelli, C., additional, Cherubini, B., additional, Surace, L., additional, Bonino, F., additional, Galli, C., additional, and Brunetto, M.R., additional

Published
2014
Full Text
View/download PDF

46. P688 LONG-TERM OUTCOME OF INACTIVE AND LOW VIREMIC HBeAg NEGATIVE ACTIVE CARRIERS: BENIGN ONE DIRECTION TRANSITION TOWARDS SPONTANEOUS HBsAg CLEARANCE

Author

Surace, L., primary, Colombatto, P., additional, Oliveri, F., additional, Moriconi, F., additional, Cavallone, D., additional, Coco, B., additional, Ciccorossi, P., additional, Rastelli, C., additional, Romagnoli, V., additional, Cherubini, B., additional, Ricco, G., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2014
Full Text
View/download PDF

48. Long-term outcome of inactive and low viremic HBeAg negative active carriers: Benign one direction transition towards spontaneous HBsAg clearance

Author

Surace, L., primary, Colombatto, P., additional, Oliveri, F., additional, Moriconi, F., additional, Cavallone, D., additional, Coco, B., additional, Ciccorossi, P., additional, Rastelli, C., additional, Romagnoli, V., additional, Cherubini, B., additional, Ricco, G., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2014
Full Text
View/download PDF

49. Early prediction of sustained virologic response by HCV Core Ag kinetics in chronic hepatitis C patients treated with Peginterferon plus Ribavirin

Author

Ricco, G., primary, Moriconi, F., additional, Colombatto, P., additional, Oliveri, F., additional, Cavallone, D., additional, Ciccorossi, P., additional, Coco, B., additional, Romagnoli, V., additional, Rastelli, C., additional, Cherubini, B., additional, Surace, L., additional, Bonino, F., additional, Galli, C., additional, and Brunetto, M.R., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results